Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | $28.15 |
| 52 Week Low | $6.55 |
| Target Price | $28.00 |
| Ticker | AMAM:UW |
| Composite Ticker | AMAM:US |
| Security Name | Ambrx Biopharma Inc. |
| Type | Ordinary Shares |
| Class | N/A |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | N/A |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG01JPVBFD1 |
| Composite FIGI | BBG01JPV4H09 |
| Share Class FIGI | N/A |
| FIGI Unique ID | N/A |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | N/A |
| Beta | 3.6185 |
| 1-year beta | 3.8662 |
| 3-year beta | 3.6185 |
| 5-year beta | 3.6185 |
| 7-year beta | 3.6185 |
| 10-year beta | 3.6185 |
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.
